• It is an Antineoplastic agent and Monoclonal antibody. It binds to the Epidermal Growth Factor Receptor (EGFR) and aids in treating cancer.
• BIOMAb EGFR® targets the epidermal growth factor receptor (EGFR) present on the cell surface. The binding of certain growth factors to this receptor starts a series of events that are essential for cell growth, differentiation, and survival (both normal and cancerous). In cancerous cells there is an over expression of EGFR leading to uncontrolled cell growth, proliferation, survival and creation of new blood vessels. A very high level of EGFR is seen in many solid tumors and has been associated with poor treatment outcomes. BIOMAb EGFR® binds to the site on EGFR where the growth factors are supposed to bind and thus prevents cancer cells from proliferating, making new blood vessels and evading death. BIOMAb EGFR® also helps the body's immune system in recognizing the cancerous cells and fighting against them.
• Based on the experience of thousands of patients, BIOMAb EGFR® remains to be the unique monoclonal antibody of its class that has rarely exhibited any severe skin rashes till date.
• Studies conducted worldwide prove that BIOMAb EGFR® has a very good safety profile. In an Indian study of 92 patients with head and neck cancer, there have not been any incidences of severe skin rashes, hypomagnesaemia (low magnesium count) and other classical EGFR inhibition related side effects.
• The superior safety profile of BIOMAb EGFR® can be attributed to its proven unique molecular profile leading to its rapid clearance from normal cells, high tumor selectivity and specificity and its ability to enhance the antitumor effects of radiotherapy and chemotherapy.
• BIOMAb EGFR® has been seen to bind strongly to the tumor cells with high EGFR expression whereas in normal cells with low EGFR expression the binding is temporary or negligible. Unlike other EGFR inhibitors, there are negligible incidences of debilitating skin rashes, hypomagnesaemia or any other such side effects with BIOMAb EGFR® treatment.

Common Causes :

• (including , sometimes called “chewing ” or “snuff”) and alcohol are the most common risk factors of head & neck cancers, particularly those of the oral cavity, oropharynx, hypopharynx, and larynx.
• Eighty-five percent of head & neck cancers are linked to use. People who use both and alcohol are at a greater risk of developing these cancers than those who use either or alcohol.

• It is an Antineoplastic agent and Monoclonal antibody. It binds to the Epidermal Growth Factor Receptor (EGFR) and aids in treating cancer.
• BIOMAb EGFR® targets the epidermal growth factor receptor (EGFR) present on the cell surface. The binding of certain growth factors to this receptor starts a series of events that are essential for cell growth, differentiation, and survival (both normal and cancerous). In cancerous cells there is an over expression of EGFR leading to uncontrolled cell growth, proliferation, survival and creation of new blood vessels. A very high level of EGFR is seen in many solid tumors and has been associated with poor treatment outcomes. BIOMAb EGFR® binds to the site on EGFR where the growth factors are supposed to bind and thus prevents cancer cells from proliferating, making new blood vessels and evading death. BIOMAb EGFR® also helps the body's immune system in recognizing the cancerous cells and fighting against them.
• Based on the experience of thousands of patients, BIOMAb EGFR® remains to be the unique monoclonal antibody of its class that has rarely exhibited any severe skin rashes till date.
• Studies conducted worldwide prove that BIOMAb EGFR® has a very good safety profile. In an Indian study of 92 patients with head and neck cancer, there have not been any incidences of severe skin rashes, hypomagnesaemia (low magnesium count) and other classical EGFR inhibition related side effects.
• The superior safety profile of BIOMAb EGFR® can be attributed to its proven unique molecular profile leading to its rapid clearance from normal cells, high tumor selectivity and specificity and its ability to enhance the antitumor effects of radiotherapy and chemotherapy.
• BIOMAb EGFR® has been seen to bind strongly to the tumor cells with high EGFR expression whereas in normal cells with low EGFR expression the binding is temporary or negligible. Unlike other EGFR inhibitors, there are negligible incidences of debilitating skin rashes, hypomagnesaemia or any other such side effects with BIOMAb EGFR® treatment.

Common Causes :

• (including , sometimes called “chewing ” or “snuff”) and alcohol are the most common risk factors of head & neck cancers, particularly those of the oral cavity, oropharynx, hypopharynx, and larynx.
• Eighty-five percent of head & neck cancers are linked to use. People who use both and alcohol are at a greater risk of developing these cancers than those who use either or alcohol.